New hope for colitis sufferers: drug BRS201 trial launches

NCT ID NCT06420492

First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 26 times

Summary

This study tests a new oral drug called BRS201 for people with severe ulcerative colitis who haven't gotten better with standard treatments. Over 12 weeks, 20 adults will take the drug twice daily and may also receive an IV dose. The goal is to see if the drug can reduce symptoms and improve sulfur metabolism markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Chestnut Hill, Massachusetts, 02467, United States

  • Brigham and Women's Hospital

    RECRUITING

    Chestnut Hill, Massachusetts, 02467, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.